AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical ...
The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics' first patient dosing in ...
NEW YORK, May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in ...
Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating ...
After Apellis Pharmaceuticals and partner Sobi ran into a clinical setback and ended the open-label extension arm of a study testing their amyotrophic lateral sclerosis (ALS) candidate, the companies ...
Athira Pharma, Inc. has announced favorable results from a Phase 1 clinical trial of its drug candidate ATH-1105, which targets neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). The ...
Bolstering a Resurgence in Novel Approaches to Target Underlying Pathology, Address Disease Heterogeneity and Restore Hope in a More Transformative Wave of ALS and FTD Therapies. Uniting ALS Biotech, ...
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical ...
Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), ...
A triple combination therapy identified using newly developed cell models is showing promise for treating sporadic ALS, per a study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results